Innovations in clinical neuroscience最新文献

{"title":"More Evidence is Needed Before Recommending Magic Mushrooms for the Treatment of Complicated Migraines.","authors":"Josef Finsterer","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 1-3","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positive Psychiatry and Healthy Lifestyle Interventions Augmenting Psychotherapy for Mood Disorders.","authors":"Terry Correll, Julie Gentile, Andrew B Correll","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Healthy lifestyle and positive psychiatry interventions can complement the treatment of mood disorders and help individuals who are not experiencing as much happiness and satisfaction in their lives as they desire. This article gives examples of an optimal psychiatric treatment plan that would potentially include psychotherapy, psychotropic medications, and/or individualized and targeted healthy lifestyle and positive psychiatry interventions to not only treat mental illness, but also enhance overall wellbeing.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 1-3","pages":"20-27"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Report of Summer Seasonal Affective Disorder: An Underrecognized Condition in Tropical Regions.","authors":"Mohammad Ibrahim, Hassam Nasir Khan Alizai, Izma Shahid, Muhammad Hannan Malik","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This case report presents a 35-year-old male patient from Lahore, Pakistan, who experienced recurring seasonal depressive symptoms from May to September for seven years. The patient exhibited symptoms including feelings of worthlessness, low mood, loss of appetite, decreased energy, anhedonia, and psychomotor retardation during the summer months, with a return to normal functioning outside of these months. The patient remained undiagnosed throughout this time. After multiple unsuccessful treatments from various facilities, he presented to our outpatient clinic for evaluation. Subsequently, he was admitted to the inpatient unit, where regular assessments diagnosed him with summer seasonal affective disorder (SAD), a rare and less-recognized form of SAD. After further evaluation, a treatment plan was devised that included slowly tapering off previous medications and initiating bupropion (a United States Food and Drug Administration [FDA]-approved medication for SAD) along with cognitive behavioral therapy. The patient subsequently fully recovered on bupropion and returned to normal functioning. The case highlights the challenges in diagnosing and treating summer SAD, particularly in tropical climates, where it is less recognized than winter SAD due to the scarcity of literature and awareness regarding it. Additionally, the positive response to bupropion suggests its potential efficacy for summer SAD. This report emphasizes the importance of considering regional and seasonal factors in psychiatric diagnoses and calls for increased awareness of and research on summer SAD, especially in countries such as Pakistan. The authors note this as potentially the first reported case of summer SAD in Pakistan, the sixth-most populous country globally. This highlights the need for a better understanding and management of seasonal disorders in diverse geographical contexts.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 1-3","pages":"51-53"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virtual Reality as a Nonpharmacological Tool for Acute Pain Management: A Scoping Review.","authors":"Ragaviveka Gopalan, Himanshi Pande, Saralya Narayanan, Adith Chinnaswami","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Acute pain (AP) is a prevalent symptom in hospital settings, affecting up to 84 percent of the patients seeking healthcare services. It significantly impacts an individual's quality of life, with inadequate management resulting in slower recovery, increased cost of care, and a greater risk of developing chronic pain. While pharmacological approaches are effective, they are associated with numerous side effects, including nausea, addiction, and the possibility of fatal overdoses. Given this, virtual reality (VR) offers an innovative avenue to manage AP effectively while minimizing the effects of drugs.</p><p><strong>Objectives: </strong>This study aims to map the extent of literature on utilizing VR as a tool for the nonpharmacological management of AP. Specifically, this review attempts to understand the characteristics of the populations using VR for AP management, the technical specifications and mechanisms used to alleviate AP, and the overall effectiveness of VR in managing AP.</p><p><strong>Methods: </strong>A scoping review was conducted to identify literature from the following electronic databases: PubMed, ScienceDirect, ERIC, and Google Scholar. To be included in this review, articles had to focus on AP in both adult and pediatric populations and address AP using VR in any clinical or care setting. The search was limited to peer-reviewed, English-language, quantitative research articles published between 2000 and 2024.</p><p><strong>Results: </strong>A total of 97 studies were identified. Sixty-six percent of studies demonstrated the efficacy of VR as an analgesic, outperforming traditional nonpharmacological approaches (eg, standard of care, mobile phones). Distraction was the most effective VR mechanism for pain management, showing efficacy in 86.9 percent of studies. The most common focus was on needle-related pain (30.9%), followed by dental and perioperative pain (15.5% each). VR was most effective in wound care (87.5%), followed by labor-related (83.33%) and dental (80%) pain.</p><p><strong>Conclusion: </strong>VR is a promising tool for managing AP, offering considerable benefits in terms of patient care, patient experience, and reduction in drug-related side effects. The high efficacy rates for wound care, labor-related pain, and dental pain highlight the potential for VR to be integrated into standard pain management protocols. However, further research, with rigorous research design, is required to standardize VR interventions and optimize their effectiveness across different patient populations and pain contexts.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 1-3","pages":"28-50"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the Reporting Quality of Randomized, Controlled Trials of Percutaneous Patent Foramen Ovale Closure for the Treatment of Migraine Based on the CONSORT Statement.","authors":"Eirini Beneki, Kyriakos Dimitriadis, Elias Zintzaras, Panagiotis Kostakis, Constantina Aggeli, Konstantinos Tsioufis","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The presence of patent foramen ovale (PFO) has been associated with migraine. Several retrospective, nonrandomized studies support reduction of migraine frequency and severity after PFO closure. However, three randomized, controlled trials (RCTs) have not met their primary efficacy endpoints, and their reporting quality has not been assessed. The present study aims to determine the reporting quality of RCTs focusing on the PFO closure for the treatment of migraine according to the revised Consolidated Standards of Reporting Trials (CONSORT) 2010 checklist. Systematic searches of two databases (MEDLINE/PubMed and Cochrane Library) were conducted. The primary objective was to establish the mean CONSORT adherence of RCTs of PFO closure for the migraine treatment, and secondary objectives were the calculation of adherence per CONSORT item and the effect of CONSORT statement in high-ranked medical journals. A 37-item questionnaire based on the CONSORT 2010 checklist was used to assess the reporting quality. Adequate adherence to the CONSORT statement was defined as reporting over 70 percent of the items. The search identified three eligible articles for analysis. The mean adherence was 69.66±4.49 percent. Only one of the studies achieved a good reporting quality (≥75%). Twenty-six of the 37 items of the CONSORT checklist (70.3%) were reported in more than half of the studies. Quality of reporting in RCTs focusing on the PFO closure for the treatment of migraine remains unsatisfactory. Further improvement of reporting quality is essential to assess the validity of clinical research.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 1-3","pages":"14-19"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"More Evidence is Needed Before Recommending Magic Mushrooms for the Treatment of Complicated Migraines\".","authors":"David W Lawrence","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 1-3","pages":"11-12"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Differences in Brain Networks Might Explain Why Female Patients with Schizophrenia Experience More Side Effects from Antipsychotic Medications.","authors":"Takahiko Nagamine","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 1-3","pages":"12-13"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Azithromycin-induced Adolescent Manic Episode with Psychotic Features: A Case Report.","authors":"Amro H Mohammad, Marie-Pier Lecours, Emmanuel Adams-Gelinas, Arshia Kakkar, Anthi Stefatos","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Premarketing clinical trials of azithromycin (AZT) computed a 0.8-percent incidence rate of neurological symptoms, such as headaches and vertigo. Postmarket surveillance reported on psychiatric reactions to AZT that included aggression, agitation, anxiety, delirium, and hallucinations. Nonetheless, these observations do not provide further insight on patient characteristics, disease course, and medical intervention.</p><p><strong>Methods: </strong>We report the case of an 18-year-old male patient with no prior medical or psychiatric history who developed profound religious delusions and unusual behavior hours after taking a one-time AZT dose of 1,000mg for a confirmed sexually transmitted <i>Chlamydia trachomatis</i> infection.</p><p><strong>Results: </strong>The patient presentation and clinical history satisfied criteria for a manic episode with psychotic features lasting for at least one week. As per <i>The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition</i> (DSM-5) criteria, the patient was diagnosed with medication-induced manic episode with psychotic features. At presentation, the patient received an intramuscular injection consisting of haloperidol 10mg and diphenhydramine 50mg, followed by olanzapine 10mg, diazepam 20mg, and lorazepam 5mg orally on account of his severe agitation. The patient was then maintained on olanzapine 30mg and lorazepam 5mg for six days. Lorazepam was then titrated down to 4mg for two days, then to 3mg in the outpatient setting. The patient demonstrated relative improvement in both the inpatient and outpatient settings, with no relapse despite eventual discontinuation of psychotropic medication.</p><p><strong>Conclusion: </strong>We report, to our knowledge for the first time, that AZT monotherapy might induce a manic episode with psychotic features in adolescent patients with no psychiatric medical history.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 1-3","pages":"54-57"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143998359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Management: I've Been Sued, Now What! Part 1.","authors":"Denita Neal","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation and other resources offered to health care providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company. Other risk management consulting companies or insurance carriers might provide different advice, and readers should take this into consideration. The information in this column does not constitute legal advice. For legal advice, contact your personal attorney. <b>Note:</b> The information and recommendations in this article are applicable to physicians and other health care professionals so \"clinician\" is used to indicate all treatment team members.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 1-3","pages":"58-59"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing Sexual Assault in Intellectual Disability.","authors":"Julie P Gentile, Larrilyn Grant","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Prevention of sexual assault in intellectual disability (ID) begins with defining the problem. There are identified risk factors and barriers faced by adults with ID who experience sexual assault. Research shows that individuals with ID are victimized by sexual assault at rates substantially higher than the general population. The perpetrators are usually trusted individuals in their environment, such as peers, caregivers, or family members. Effective prevention efforts require identifying risk factors and employing public health strategies. Finally, widespread adoption of evidence-based educational programs and proven strategies are necessities.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"21 10","pages":"15-21"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11709440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}